Cargando…
Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
Neoadjuvant treatment of breast cancer is applied to an increasing extent, but treatment response varies and side effects pose a challenge. The vitamin E isoform delta-tocotrienol might enhance the efficacy of chemotherapy and reduce the risk of side effects. The aim of this study was to investigate...
Autores principales: | Kjær, Ina Mathilde, Kahns, Søren, Timm, Signe, Andersen, Rikke Fredslund, Madsen, Jonna Skov, Jakobsen, Erik Hugger, Tabor, Tomasz Piotr, Jakobsen, Anders, Bechmann, Troels |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209064/ https://www.ncbi.nlm.nih.gov/pubmed/37225860 http://dx.doi.org/10.1038/s41598-023-35362-7 |
Ejemplares similares
-
Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer
por: Kjær, Ina Mathilde, et al.
Publicado: (2020) -
Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study
por: Kjær, Ina Mathilde, et al.
Publicado: (2020) -
Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification
por: Sørensen, Patricia Diana, et al.
Publicado: (2015) -
Predicting brain metastases of breast cancer based on serum S100B and serum HER2
por: BECHMANN, TROELS, et al.
Publicado: (2013) -
New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer
por: Horn, Peer, et al.
Publicado: (2014)